- Home
- IGIC vs SNDX Comparison
IGIC vs SNDX Comparison
Compare IGIC & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGIC
- SNDX
- Stock Information
- Founded
- IGIC 2001
- SNDX 2005
- Country
- IGIC Jordan
- SNDX United States
- Employees
- IGIC N/A
- SNDX N/A
- Industry
- IGIC Property-Casualty Insurers
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- IGIC Finance
- SNDX Health Care
- Exchange
- IGIC Nasdaq
- SNDX Nasdaq
- Market Cap
- IGIC 1.0B
- SNDX 1.1B
- IPO Year
- IGIC N/A
- SNDX 2016
- Fundamental
- Price
- IGIC $23.94
- SNDX $9.28
- Analyst Decision
- IGIC Buy
- SNDX Strong Buy
- Analyst Count
- IGIC 2
- SNDX 11
- Target Price
- IGIC $31.50
- SNDX $35.91
- AVG Volume (30 Days)
- IGIC 144.7K
- SNDX 2.5M
- Earning Date
- IGIC 05-06-2025
- SNDX 05-05-2025
- Dividend Yield
- IGIC 3.95%
- SNDX N/A
- EPS Growth
- IGIC 1.83
- SNDX N/A
- EPS
- IGIC 2.73
- SNDX N/A
- Revenue
- IGIC $537,909,000.00
- SNDX $43,722,000.00
- Revenue This Year
- IGIC $34.93
- SNDX $274.51
- Revenue Next Year
- IGIC $6.00
- SNDX $140.65
- P/E Ratio
- IGIC $8.63
- SNDX N/A
- Revenue Growth
- IGIC 5.21
- SNDX N/A
- 52 Week Low
- IGIC $13.48
- SNDX $9.66
- 52 Week High
- IGIC $27.76
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- IGIC 47.37
- SNDX 33.02
- Support Level
- IGIC $22.78
- SNDX $9.67
- Resistance Level
- IGIC $23.80
- SNDX $11.48
- Average True Range (ATR)
- IGIC 0.86
- SNDX 1.00
- MACD
- IGIC -0.10
- SNDX -0.34
- Stochastic Oscillator
- IGIC 32.04
- SNDX 0.80
About IGIC International General Insurance Holdings Ltd.
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.